IL270395B - Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil - Google Patents

Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Info

Publication number
IL270395B
IL270395B IL270395A IL27039519A IL270395B IL 270395 B IL270395 B IL 270395B IL 270395 A IL270395 A IL 270395A IL 27039519 A IL27039519 A IL 27039519A IL 270395 B IL270395 B IL 270395B
Authority
IL
Israel
Prior art keywords
therapeutic agent
pharmaceutically acceptable
acceptable salt
donepezil
dimethylpyridin
Prior art date
Application number
IL270395A
Other languages
English (en)
Hebrew (he)
Other versions
IL270395A (cg-RX-API-DMAC7.html
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IL270395A publication Critical patent/IL270395A/en
Publication of IL270395B publication Critical patent/IL270395B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL270395A 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil IL270395B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513692P 2017-06-01 2017-06-01
PCT/JP2018/020638 WO2018221545A1 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤

Publications (2)

Publication Number Publication Date
IL270395A IL270395A (cg-RX-API-DMAC7.html) 2020-02-27
IL270395B true IL270395B (en) 2022-08-01

Family

ID=64455958

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270395A IL270395B (en) 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Country Status (13)

Country Link
US (1) US11833146B2 (cg-RX-API-DMAC7.html)
EP (1) EP3632439B1 (cg-RX-API-DMAC7.html)
JP (2) JP7079777B2 (cg-RX-API-DMAC7.html)
KR (1) KR102627787B1 (cg-RX-API-DMAC7.html)
CN (1) CN110603040B (cg-RX-API-DMAC7.html)
AU (1) AU2018276565A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019023569A2 (cg-RX-API-DMAC7.html)
CA (1) CA3060030A1 (cg-RX-API-DMAC7.html)
ES (1) ES2980131T3 (cg-RX-API-DMAC7.html)
IL (1) IL270395B (cg-RX-API-DMAC7.html)
RU (1) RU2019135834A (cg-RX-API-DMAC7.html)
SG (2) SG11201909595VA (cg-RX-API-DMAC7.html)
WO (1) WO2018221545A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
JP7177772B2 (ja) 2017-06-01 2022-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
KR102271305B1 (ko) 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272907B1 (ko) 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272910B1 (ko) 2021-01-28 2021-07-06 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220140960A (ko) 2021-04-12 2022-10-19 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220146095A (ko) 2021-04-23 2022-11-01 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR102311224B1 (ko) * 2021-04-23 2021-10-13 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
DE69518075T2 (de) 1994-05-24 2001-03-22 F. Hoffmann-La Roche Ag, Basel Tricyclische dicarbonylderivate
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
EP1537106A1 (en) 2002-08-07 2005-06-08 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
US20060035920A1 (en) 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
WO2007032466A1 (ja) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. 複素環化合物、その製造方法並びに用途
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
AU2007332439A1 (en) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Therapeutic agent for urinary tract disease
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
AU2010219598A1 (en) 2009-03-05 2011-09-22 Astellas Pharma Inc. Quinoxaline compounds
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
ES2583528T3 (es) 2010-09-07 2016-09-21 Astellas Pharma Inc. Compuesto de pirazoloquinolina
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
JP2013051639A (ja) 2011-08-31 2013-03-14 Kyocera Document Solutions Inc 画像形成装置
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
SI2573073T1 (sl) 2011-09-26 2015-02-27 Sanofi Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba
CN103930423B (zh) 2011-10-07 2015-09-16 卫材Rd管理有限公司 吡唑并喹啉衍生物
JP5666755B1 (ja) 2013-04-05 2015-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体の塩およびその結晶
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
JP7177772B2 (ja) 2017-06-01 2022-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
CN108563565B (zh) 2018-04-08 2021-12-17 中国人民解放军海军工程大学 飞行着陆引导系统可靠性定量分析模型建立方法

Also Published As

Publication number Publication date
US11833146B2 (en) 2023-12-05
SG10202113198TA (en) 2021-12-30
JP7288999B2 (ja) 2023-06-08
SG11201909595VA (en) 2019-11-28
JP7079777B2 (ja) 2022-06-02
US20200129501A1 (en) 2020-04-30
AU2018276565A1 (en) 2019-11-07
EP3632439A4 (en) 2021-02-17
CN110603040A (zh) 2019-12-20
RU2019135834A3 (cg-RX-API-DMAC7.html) 2021-10-15
EP3632439B1 (en) 2024-03-27
RU2019135834A (ru) 2021-07-13
IL270395A (cg-RX-API-DMAC7.html) 2020-02-27
KR102627787B1 (ko) 2024-01-23
CN110603040B (zh) 2023-02-28
WO2018221545A1 (ja) 2018-12-06
CA3060030A1 (en) 2018-12-06
EP3632439A1 (en) 2020-04-08
BR112019023569A2 (pt) 2020-06-02
ES2980131T3 (es) 2024-09-30
JPWO2018221545A1 (ja) 2020-04-02
KR20200010224A (ko) 2020-01-30
JP2022110143A (ja) 2022-07-28

Similar Documents

Publication Publication Date Title
IL270394B (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
RU2019135834A (ru) Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
JP2022110143A5 (cg-RX-API-DMAC7.html)
WO2003070236A3 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
EP4344743A3 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
NZ766835A (en) Pharmaceutical compounds
WO2001098290A3 (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2011106729A3 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
HRP20110570T1 (hr) Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora
JOP20210116A1 (ar) مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
MX2019013397A (es) Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina.
WO2023178111A3 (en) Organic compounds
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
RU2019135261A (ru) Фармацевтическая композиция, содержащая ингибитор pde9
JP2020521726A5 (cg-RX-API-DMAC7.html)
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
ZA202309001B (en) Abhd6 antagonist
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
NO20065551L (no) Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin
NO20054994L (no) Anvendelse av karbamazepinderivater for behandling av aggresjon hos demenspasienter
EA202190558A1 (ru) Новые производные тиазола и их фармацевтически приемлемые соли
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
EP1741430A4 (en) MEANS FOR THE TREATMENT OF PSYCHONEUROTIC DISEASES